Javascript must be enabled to continue!
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
View through CrossRef
AbstractObjectiveTo analyse the demographic, clinical and laboratory data of Beninese patients with haemophilia.MethodA prospective survey was conducted in three different hospitals of Benin from April 2021 to March 2022, to analyse clinical and biological features of patients with haemophilia previously diagnosed or identified based on personal/family history.ResultsA total of 101 patients were studied, 97 with haemophilia A and 4 with haemophilia B, including 26 new cases identified after family investigation. Their median age was 11 years, and the most frequent initial manifestations were cutaneous‐mucosal haemorrhages (29.70%) and post‐circumcision haemorrhages (25.74%). Previous joint bleedings were present in 77% of them, with an arthropathy in 65 cases, which particularly affected the knees (75%), elbows (41%) and ankles (29%). Factor VIII (FVIII) levels combined with activated partial thromboplastin time (APTT) values did not always enable, as would be expected, the distinction between severe and moderate haemophilia, since they were >1 IU/dl in 31 of 74 patients with APTT > 80 s, and between 1 and 2 IU/dl in 26 other cases with previous joint haemorrhages, including 18 with chronic arthropathy. Therefore, for these patients, severe haemophilia could not be excluded, and this uncertainty probably reflects technical difficulties affecting the pre‐analytical and analytical stages of the APTT and FVIII/IX assays.ConclusionOur study proved that haemophilia is a significant reality in Benin, but also remains under‐diagnosed in some districts of the country. In addition, more reliable biological tests are needed in the future to better define the severity of the disease and improve treatment of patients.
Title: Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
Description:
AbstractObjectiveTo analyse the demographic, clinical and laboratory data of Beninese patients with haemophilia.
MethodA prospective survey was conducted in three different hospitals of Benin from April 2021 to March 2022, to analyse clinical and biological features of patients with haemophilia previously diagnosed or identified based on personal/family history.
ResultsA total of 101 patients were studied, 97 with haemophilia A and 4 with haemophilia B, including 26 new cases identified after family investigation.
Their median age was 11 years, and the most frequent initial manifestations were cutaneous‐mucosal haemorrhages (29.
70%) and post‐circumcision haemorrhages (25.
74%).
Previous joint bleedings were present in 77% of them, with an arthropathy in 65 cases, which particularly affected the knees (75%), elbows (41%) and ankles (29%).
Factor VIII (FVIII) levels combined with activated partial thromboplastin time (APTT) values did not always enable, as would be expected, the distinction between severe and moderate haemophilia, since they were >1 IU/dl in 31 of 74 patients with APTT > 80 s, and between 1 and 2 IU/dl in 26 other cases with previous joint haemorrhages, including 18 with chronic arthropathy.
Therefore, for these patients, severe haemophilia could not be excluded, and this uncertainty probably reflects technical difficulties affecting the pre‐analytical and analytical stages of the APTT and FVIII/IX assays.
ConclusionOur study proved that haemophilia is a significant reality in Benin, but also remains under‐diagnosed in some districts of the country.
In addition, more reliable biological tests are needed in the future to better define the severity of the disease and improve treatment of patients.
Related Results
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Summary. Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia trea...
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
A transgender person with haemophilia
A transgender person with haemophilia
Abstract
Introduction
Transgender people face many obstacles to accessing healthcare but cultural changes are likely to i...
Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A
Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A
AbstractBackgroundDecreased bone mineral density (BMD) is a significant morbidity in haemophilia. Vitamin D is important for the bone health of people with haemophilia. Regular fac...
Haemophilia care in Iraq; a multi-centre study
Haemophilia care in Iraq; a multi-centre study
Objectives: To evaluate the level of care available to haemophilia patients.
Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March...
Haemophilia treatment in 2030
Haemophilia treatment in 2030
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...

